ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 713

Interferon Regulatory Factor 2 Haploinsufficiency Deteriorates Imiquimod-Induced Psoriasis-Like Skin Inflammation

Takayuki Kimura1, Makoto Sugaya2, Makiko Kawaguchi1, Sohshi Morimura1, Hiraku Suga1 and Shinichi Sato3, 1Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, 2Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 3Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: IL-23 and toll-like receptors

  • Tweet
  • Email
  • Print
Session Information

Title: T-cell Biology and Targets in Autoimmune Disease: Signaling Pathways in T-cell Differentiation

Session Type: Abstract Submissions (ACR)

Background/Purpose: Psoriasis is a T-cell-mediated immunological skin disease with a complex pathogenesis where both genetic and environmental factors are involved. Interferon regulatory factor (IRF)-2 is one of the potential susceptibility genes for psoriasis. IRFs are a family of transcription factors that regulate expression of pro- and anti-inflammatory genes. IRF-2 protein binds the same regulatory sequence as IRF-1, which suppresses transcription of interferon-inducible genes. Topical application of imiquimod, a TLR7/8 ligand, induces psoriasis-like inflamed skin lesions via the IL-17/23 axis. We hypothesized that combination of IRF2 gene status and environmental stimulus (imiquimod) would cause severer skin lesions, serving as a good model of human psoriasis.

Methods: IRF-2+/- and wild-type (WT) mice received a daily topical dose of 62.5 mg imiquimod cream (5%) on a shaved back and ears for 6 consecutive days. Erythema, scaling, and skin thickness were independently scored every day. Total RNA was isolated from skin specimens on day 2 and 5 and reverse-transcribed into cDNA. Macrophage were harvested from peritoneal cavity of naive IRF-2+/- and WT mice and stimulated with 1 or 5 μg/ml of imiquimod for 6 or 24 hours in vitro. Total RNA was isolated and reverse-transcribed into cDNA. Messenger RNA expression of different cytokines was analyzed using a real-time PCR quantification method.

Results: Imiquimod-induced skin inflammation assessed by erythema, scaling, and skin thickness was severer in IRF-2+/- mice than WT mice. In inflamed skin, mRNA expression of TNF-α, IL-12/23p40, IL-23p19, and inducible nitric oxide synthase (iNOS) was increased on day 2, and that of TNF-α, IL-12p35, IL-17A, and iNOS was increased on day 5 in IRF-2+/- mice compared to WT mice. In peritoneal macrophage of IRF-2+/- and WT mice stimulated with imiquimod, mRNA levels of TNF-α, IL-12/23p40, IL-23p19, IL-12p35, IL-36α, and IL-36γ were significantly elevated compared to non-stimulated macrophages. Interestingly, macrophages harvested from IRF-2+/- mice expressed higher levels of TNF-α, IL-12/23p40, IL-23p19 compared to those from WT mice 24 hours after stimulation, while they expressed similar levels of IL-12p35, IL-36α, and IL-36γ. Moreover, elevated mRNA expression of iNOS was observed only in stimulated macrophages derived from IRF-2+/- mice.

Conclusion: These results suggest that IRF-2 haploinsufficiency and a TLR7/8 stimulator regulate cytokine expression in a different manner, developing Th17-associated skin inflammation, which may serve as a good model of human psoriasis.


Disclosure:

T. Kimura,
None;

M. Sugaya,
None;

M. Kawaguchi,
None;

S. Morimura,
None;

H. Suga,
None;

S. Sato,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interferon-regulatory-factor-2-haploinsufficiency-deteriorates-imiquimod-induced-psoriasis-like-skin-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology